Half-Life and Time to Steady State

The elimination half-life (t½) is the time required for plasma drug concentration to fall by 50%. For drugs following first-order kinetics, t½ is constant and independent of dose: t½ = 0.693 / ke, where ke is the first-order elimination rate constant. This relationship can also be expressed in terms of the primary PK parameters: t½ = 0.693 × Vd / CL. This equation reveals an important insight — half-life is a derived parameter, not a primary one. It increases when Vd increases (more drug stored in tissues, slowly returning to plasma) or when CL decreases (impaired elimination). A drug with a long half-life could be due to either large Vd or low clearance, and these have very different clinical implications.

Half-life determines two critical clinical timing parameters: time to steady state and washout time. For drugs given as repeated doses, the plasma concentration accumulates until the rate of elimination equals the rate of input. This steady state is reached after approximately 4–5 half-lives, regardless of dose or dosing frequency. Doubling the dose does not accelerate attainment of steady state — it only doubles the eventual steady-state concentration. Similarly, washout after stopping a drug takes approximately 4–5 half-lives. Digoxin (t½ ≈ 36–48 h) takes approximately 7–10 days to reach steady state; amiodarone (t½ ≈ 40–55 days) may take months. Conversely, after stopping amiodarone, its effects persist for weeks to months.

The dosing interval relative to t½ determines the degree of fluctuation between peak and trough concentrations. When τ (dosing interval) << t½, fluctuation is minimal and concentrations are quasi-continuous. When τ >> t½, significant peaks and troughs occur. The peak-to-trough ratio is: Cpeak/Ctrough = e^(ke × τ). For aminoglycosides, once-daily extended-interval dosing exploits a τ >> t½ relationship to achieve high peaks (concentration-dependent killing) while allowing troughs to fall below the threshold for nephrotoxicity.

Loading doses exploit the relationship between Vd and target concentration to rapidly achieve therapeutic levels without waiting multiple half-lives. Without a loading dose, a patient started on digoxin would take 7–10 days to reach therapeutic concentrations — clinically unacceptable in atrial fibrillation with rapid ventricular response. The loading dose = Vd × target Cp / F brings the concentration immediately to the target. The subsequent maintenance dose then replaces drug eliminated each interval.

Context-sensitive half-life is a refinement relevant to infusions of drugs that distribute into peripheral compartments. For drugs like fentanyl or propofol described by multi-compartment models, the apparent t½ after stopping an infusion depends on infusion duration because drug redistributes from peripheral to central compartments after the infusion ends. The half-life relevant to clinical effect termination may be much longer than the simple t½ derived from two-compartment elimination.

In New Zealand pharmacy practice, t½ guides counselling around missed doses, drug holidays, and washout periods. For example, advising a patient that fluoxetine (t½ ≈ 1–6 days for active metabolite norfluoxetine) does not require bridging when switching antidepressants contrasts sharply with the guidance for venlafaxine (t½ ≈ 5 h), which requires gradual tapering to avoid discontinuation syndrome.